|
|
News Breaks | | | | March 7, 2013 | | 08:16 EDT |  | NWBO | Northwest Biotherapeutics provides guidance on Phase III trial enrollment
Northwest Biotherapeutics announced that it expects to complete enrollment in its 312-patient Phase III clinical trial for Glioblastoma multiforme brain cancer within a period that is faster or more efficient than relevant comparison trials with immune therapies for the same brain cancer. The company anticipates completing enrollment of its Phase III trial by Q1 or early Q2 of next year, and expects to reach its first interim analysis for efficacy by approximately Q3 of this year. NW Bio expects to complete enrollment in its phase III trial by Q1 or early Q2 of next year - an overall enrollment period of 14 or 15 calendar quarters, including both the 2008 period and the period since Q2 2011. | |
|
News For NWBO From The Last 14 Days Check below for free stories on NWBO the last two weeks. |
|
|
| June 13, 2013 | | 08:16 EDT | | NWBO | Northwest Biotherapeutics initiates DCVax-Direct Phase I/II trial
 Subscribe for More Information | |
|
|
|
|
|
|
